Publications by authors named "Sonam Ansel"
Article Synopsis
- This case involves a 37-year-old man with both leiomyosarcoma and tenosynovial giant cell tumor, highlighting the difficulties in diagnosing the latter due to biases in clinical assessments.
- The patient's knee symptoms temporarily worsened after treatments for leiomyosarcoma, which ultimately led to the discovery of the tenosynovial giant cell tumor following further imaging and biopsy.
- The study emphasizes the need for improved diagnostic strategies and outlines updated treatment guidelines, including novel pharmacological options for managing tenosynovial giant cell tumor effectively.
Introduction: Clinical markers of response in metastatic renal cell carcinoma (mRCC) are lacking. Low hemoglobin (Hb) is associated with poor outcomes in the IMDC risk score. This study evaluates the role of Hb as a marker of treatment outcomes in mRCC.
View Article and Find Full Text PDFIntroduction: Pembrolizumab, an immune-checkpoint inhibitor, is approved for first-line treatment of metastatic NSCLC in patients with tumours expressing programmed death-ligand 1 (PD-L1) with tumour proportion score (TPS) of ≥50%. We aimed to clarify some uncertainties regarding use of immunotherapy in patients with previous autoimmune (AI) disorders and assess real-world outcomes following treatment completion.
Methods: We performed a retrospective case record review of 82 patients with tumours expressing PD-L1 at TPS ≥ 50% and receiving first-line Pembrolizumab.